Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company focused on engineered T-cell receptor (TCR) therapies for solid tumor cancers. The company was established in July 2008 as a spin-out from Immunocore Ltd (formerly Avidex/MediGene Ltd) to develop that firm’s TCR engineering technology for adoptive T-cell therapy [1]. Adaptimmune is headquartered in Abingdon, United Kingdom [2].
Design and History
The current Adaptimmune logo is registered as a trademark of Adaptimmune Limited. The mark consists of a stylized circular design made up of several curved parallel lines, positioned to the left of the stylized word “ADAPTIMMUNE” [3]. The same circular device was also registered separately as a standalone image trademark [4].
An earlier version of the identity, registered around 2015, paired the same stylized circular design with the words “ADAPTIMMUNE TRANSFORMING T CELL THERAPY” [5]. The current wordmark-only lockup, without the tagline, reflects a later simplification of the brand.
No designer or agency has been publicly credited for the creation of the Adaptimmune mark, and no documented redesign dates or reasons have been published.
Meaning and Symbolism
Adaptimmune has not published an official explanation of the logo’s symbolism. The trademark registrations describe the device only as “a stylized circular design consisting of several curved parallel lines” [3][4]. Any interpretation linking the curved lines to cellular activity, T-cell engagement, or immunotherapy is speculative and not supported by company sources.
Typography and Design
The wordmark “ADAPTIMMUNE” appears in a stylized, all-caps letterform, as described in the trademark filing [3]. The specific typeface used has not been identified in any official or reliable source, and no brand guidelines detailing the logo’s construction, spacing, or color specifications have been published publicly.
Logo Index is an independent educational archive covering logos, visual identities and graphic design history. All trademarks and brand assets remain the property of their respective owners.
